Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study

Table 1

Demographic features of control (group 1) and antiglaucoma therapy groups (groups 2, 3, 4, and 5).

	Group 1	Group 2	Group 3	Group 4	Group 5	P
eyes	20	20	18	21	21	—
Medication	Control	Beta-blockers	Alpha adrenergic; agonists	Prostaglandin	Combination
Concentration of BAK	—	0.005%	0.005%	0.015%	—
Gender (male/female)	12/8	12/8	11/7	14/7	13/8	—
Age (yrs)	64.1 ± 15.8	60 ± 13.6	62.6 ± 12.5	61.2 ± 14.0	63.5 ± 15.2	>0.05
Treatment duration (mos)	—	11.6 ± 5.1	11.2 ± 4.5	10.9 ± 4.8	12.6 ± 5.0	>0.05

BAK: benzalkonium chloride; yrs: years; mos: months.
No statistical differences were found between the 5 groups (confidence interval: 95%).
Age and treatment duration data are expressed as mean ± standard deviation and range in parentheses. P is by analysis of variance.